Related Experiment Video
Updated: Sep 6, 2025
Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
Administration of P2X7 Receptor Blockers in Oncological Experimental Models
Elena De Marchi1, Anna Pegoraro1, Elena Adinolfi2
1Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Abstract:
The tumor microenvironment is rich in components that strongly influence cancer cell survival. One of the pivotal molecules present at the tumor bed is ATP, which has an essential role in promoting cancer proliferation and metastasis and immune responses via its receptor P2X7. Several studies have proved the efficacy of P2X7 pharmacological blockade in inhibiting primary and metastatic tumor growth in preclinical models. Here we describe the experimental procedures that we optimized to test P2X7 roles in carcinogenesis by antagonist administration. Special attention is paid to their concentrations and routes of administration. The depicted in vitro models include cell count and viability assays, which are useful to test P2X7 roles in cell proliferation and vitality, and the soft agar colony formation test that allows investigation of the transforming and invading abilities of tumor cells. We also describe systemic and intramass administration of P2X7 blockers in murine models of melanoma and leukemia. Both xenotransplant and syngeneic experimental tumor models are detailed.
Insights
Blocking the P2X7 receptor, a key molecule in the tumor microenvironment, inhibits cancer cell proliferation and metastasis. This study details optimized methods for testing P2X7 antagonists in preclinical cancer models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- The tumor microenvironment significantly impacts cancer progression.
- Adenosine triphosphate (ATP) and its receptor P2X7 play crucial roles in cancer cell proliferation, metastasis, and immune responses.
- Pharmacological blockade of P2X7 has shown promise in preclinical models for inhibiting tumor growth.
Purpose of the Study:
- To describe optimized experimental procedures for evaluating the role of P2X7 in carcinogenesis using antagonist administration.
- To detail specific concentrations and routes of administration for P2X7 antagonists.
- To present in vitro and in vivo models for assessing P2X7's impact on cancer.
Main Methods:
- In vitro assays including cell count, viability, and soft agar colony formation to assess proliferation, vitality, and transforming/invading abilities.
- In vivo administration of P2X7 blockers via systemic and intramass routes in murine models.
- Utilized both xenotransplant and syngeneic experimental tumor models for melanoma and leukemia.
Main Results:
- Established and optimized protocols for testing P2X7 antagonist efficacy.
- Demonstrated the utility of in vitro assays for evaluating P2X7's role in cancer cell behavior.
- Successfully applied systemic and intramass administration of P2X7 blockers in preclinical cancer models.
Conclusions:
- The described methodologies provide a robust framework for investigating P2X7's role in cancer.
- Optimized P2X7 antagonist administration strategies are crucial for preclinical cancer research.
- These methods facilitate the study of P2X7's influence on tumor growth and metastasis.
